Ultraviolet light drives most skin cancers, yet a meaningful share of cases develop in people whose sun exposure was never remarkable. Inherited gene variants, suppressed immune function, prior medical radiation, and a history of earlier lesions each shift risk independently of time spent outdoors. Patients who come in asking about skin cancer treatment are often surprised to learn that their personal risk profile was set long before their first sunburn.
Understanding these less-discussed factors changes how often a person should be screened, which body sites deserve attention, and how aggressively an early lesion should be treated.
Family History and the Genes That Carry It
Roughly 10 percent of people diagnosed with melanoma have at least one first-degree relative who has also had the disease. Having a parent, sibling, or child with melanoma approximately doubles an individual’s risk, and that figure climbs when two or more relatives are affected or when the relative was diagnosed before age 40.
Several inherited variants account for the strongest familial clustering:
- CDKN2A mutations, the most common high-penetrance melanoma genes, carry a lifetime melanoma risk estimated between 28 and 67 percent by age 80 depending on geography and sun exposure. Carriers also face higher pancreatic cancer risk.
- MC1R variants, which produce red hair, freckling, and poor tanning ability, raise melanoma risk even in people who do not have red hair themselves.
- Basal cell nevus syndrome (Gorlin syndrome), caused by PTCH1 mutations, produces dozens to hundreds of basal cell carcinomas beginning in adolescence, along with jaw cysts and palmar pits.
- Xeroderma pigmentosum, a rare DNA repair disorder, increases nonmelanoma skin cancer risk by roughly 1,000-fold, with first cancers often appearing before age 10.
Nevus count is partly inherited as well. People with more than 50 common moles, or with five or more atypical (dysplastic) nevi, sit in a higher risk category regardless of their sun history, according to the National Cancer Institute.
Organ Transplant Recipients Carry the Steepest Increase
Long-term immunosuppression after a solid organ transplant produces one of the largest risk multipliers in all of dermatology. Squamous cell carcinoma occurs at rates roughly 65 to 100 times higher than in the general population, and the ratio of SCC to basal cell carcinoma reverses compared with non-transplant patients.
Several details matter clinically:
- Risk rises with time since transplant, with cumulative incidence of skin cancer reaching 40 to 60 percent at 20 years in lighter-skinned recipients.
- Heart and lung recipients generally face higher risk than kidney recipients because their immunosuppressive regimens are more intense.
- Azathioprine sensitizes skin to UVA light, and voriconazole, an antifungal used after lung transplant, is independently associated with aggressive SCC.
- Tumors in this group behave more aggressively, with higher rates of local recurrence, perineural invasion, and metastasis than morphologically similar tumors in immunocompetent patients.
Transplant recipients are typically moved to full skin examinations every three to six months rather than the annual schedule used for average-risk adults.
Other Forms of Immune Suppression
Transplant medication is the clearest example, but it is far from the only one. Chronic lymphocytic leukemia raises the risk of aggressive squamous cell carcinoma roughly eight-fold and is strongly linked to Merkel cell carcinoma, an uncommon but fast-moving neuroendocrine tumor. People living with HIV have approximately double the rate of basal and squamous cell carcinoma even with well-controlled viral loads.
Patients on long-term biologics or systemic agents for psoriasis, rheumatoid arthritis, or inflammatory bowel disease show smaller but real increases, generally in the range of 1.3 to 1.7 times baseline for nonmelanoma skin cancer. Chronic oral corticosteroid use adds a modest independent effect. None of these findings argue against the medications, which treat serious disease, but they do justify a more frequent skin surveillance schedule.
Prior Radiation and Light-Based Therapies
Medical radiation delivered decades ago still surfaces in exam rooms today. Through the 1940s, 1950s, and early 1960s, low-dose X-ray and Grenz ray treatments were used for acne, tinea capitis, and enlarged thymus glands. Patients treated that way often develop basal cell carcinomas clustered on the scalp, face, and neck 20 to 50 years later, frequently in multiples.
Therapeutic radiation for breast cancer, lymphoma, or childhood malignancies carries a similar long-latency pattern within the treatment field. Psoralen plus UVA (PUVA) therapy, once a mainstay for severe psoriasis, deserves specific mention: patients who received more than 250 treatments show a squamous cell carcinoma risk roughly 14 times higher than untreated psoriasis patients, with risk concentrated on normally covered sites including the genitalia.
Anyone with this history should mention it at every dermatology visit, since the affected field may not be anywhere a clinician would otherwise prioritize.
Arsenic and Occupational Exposures
Chronic arsenic ingestion produces a distinctive pattern: multiple superficial basal cell carcinomas on the trunk, Bowen disease on non-sun-exposed skin, and keratoses on the palms and soles, usually appearing 20 to 40 years after exposure. Portions of central and upper Bucks County sit over bedrock formations where private wells have tested above the EPA limit of 10 parts per billion, so well water testing history is a reasonable question for longtime residents of the area.
Occupational exposure to coal tar, pitch, creosote, and certain industrial oils carries comparable risk, historically documented among roofers, road crews, and machinists.
How Higher-Risk Patients Should Be Monitored
Risk-based screening intervals matter more than any single preventive habit. The American Academy of Dermatology recommends regular self-examination alongside professional evaluation, and dermatologists providing skin cancer treatment generally stratify patients along these lines:
- Average risk: baseline full-body exam, then annually or as new lesions appear.
- Family history or many atypical nevi: every 6 to 12 months, often with dermoscopy and baseline total body photography.
- Prior nonmelanoma skin cancer: every 6 months for the first two years, then annually if stable.
- Transplant recipients and other significantly immunosuppressed patients: every 3 to 6 months, with a lower threshold for biopsy of any scaly or tender papule.
Chemoprevention is also available for selected patients. Oral nicotinamide at 500 mg twice daily reduced new nonmelanoma skin cancers by about 23 percent over 12 months in a randomized trial, and low-dose acitretin is used in transplant recipients with heavy tumor burden.
Frequently Asked Questions
Can You Develop Skin Cancer Without Significant Sun Exposure?
Yes, and roughly 10 to 20 percent of melanomas arise on skin that receives little or no sun, including the soles, palms, and nail beds. Acral lentiginous melanoma is the most common melanoma subtype in people with darker skin tones and has no established relationship to UV exposure.
How Soon After a Transplant Should Skin Screening Begin?
Screening should begin within the first year after transplant, before most cancers appear, so that a baseline map of existing lesions exists. Risk rises measurably after year five, but early documentation makes new growths far easier to identify.
Does a Family History of Basal Cell Carcinoma Matter, or Only Melanoma?
Family history of basal cell carcinoma raises personal risk by roughly two-fold, independent of shared sun habits and skin type. The effect is smaller than the familial signal in melanoma, but it is strong enough to justify starting routine exams earlier.
Should Genetic Testing Be Considered for Melanoma Risk?
CDKN2A testing is usually reserved for families with three or more melanoma cases, a relative diagnosed under 45, or a melanoma plus pancreatic cancer pattern. Results change screening intensity and prompt counseling for relatives, so testing is paired with a genetic counselor rather than ordered in isolation.
Schedule a Risk-Based Skin Exam in Southampton
Pennsylvania Dermatology Specialists evaluates patients with transplant histories, familial melanoma, prior radiation therapy, and recurrent lesions, and sets screening intervals around that history rather than a one-size schedule. Contact the Southampton office to arrange a full-body examination and biopsy of anything that has changed.
